Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alvotech ( (ALVO) ) has issued an announcement.
On June 4, 2025, Alvotech announced the completion of a private placement of 7,500,000 Swedish Depository Receipts and ordinary shares, raising SEK 750 million. The proceeds will be used to enhance R&D efforts, capitalize on growth opportunities, and strengthen market position. The placement attracted significant interest from institutional investors, particularly in Sweden, and aims to diversify Alvotech’s shareholder base and increase the float of SDRs on Nasdaq Stockholm.
The most recent analyst rating on (ALVO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s stock is rated moderately due to strong revenue growth and improved profitability offset by financial instability and cash flow concerns. Positive technical indicators and promising earnings guidance enhance the outlook, but valuation is moderate, and competitive pressures remain a risk.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines globally. It aims to lead in the biosimilar space by providing high-quality, cost-effective products, with two biosimilars already approved and marketed. The company has a broad pipeline targeting various diseases and has formed strategic partnerships for global reach.
Average Trading Volume: 187,275
Technical Sentiment Signal: Hold
Current Market Cap: $3.46B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.